TITLE

Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease

AUTHOR(S)
El Khoury, Joseph; Toft, Michelle; Hickman, Suzanne E; Means, Terry K.; Terada, Kinya; Geula, Changiz; Luster, Andrew D.
PUB. DATE
April 2007
SOURCE
Nature Medicine;Apr2007, Vol. 13 Issue 4, p432
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Microglia are the principal immune cells of the brain. In Alzheimer disease, these brain mononuclear phagocytes are recruited from the blood and accumulate in senile plaques. However, the role of microglia in Alzheimer disease has not been resolved. Microglia may be neuroprotective by phagocytosing amyloid-β (Aβ), but their activation and the secretion of neurotoxins may also cause neurodegeneration. Ccr2 is a chemokine receptor expressed on microglia, which mediates the accumulation of mononuclear phagocytes at sites of inflammation. Here we show that Ccr2 deficiency accelerates early disease progression and markedly impairs microglial accumulation in a transgenic mouse model of Alzheimer disease (Tg2576). Alzheimer disease mice deficient in Ccr2 accumulated Aβ earlier and died prematurely, in a manner that correlated with Ccr2 gene dosage, indicating that absence of early microglial accumulation leads to decreased Aβ clearance and increased mortality. Thus, Ccr2-dependent microglial accumulation plays a protective role in the early stages of Alzheimer disease by promoting Aβ clearance.
ACCESSION #
24629896

 

Related Articles

  • AAV1/2-mediated CNS Gene Delivery of Dominant-negative CCL2 Mutant Suppresses Gliosis, β-amyloidosis, and Learning Impairment of APP/PS1 Mice. Kiyota, Tomomi; Yamamoto, Masaru; Schroder, Bryce; Jacobsen, Michael T.; Swan, Russell J.; Lambert, Mary P.; Klein, William L.; Gendelman, Howard E.; Ransohoff, Richard M.; Ikezu, Tsuneya // Molecular Therapy;May2009, Vol. 17 Issue 5, p803 

    Accumulation of aggregated amyloid-β (Aβ) peptide was studied as an initial step for Alzheimer's disease (AD) pathogenesis. Following amyloid plaque formation, reactive microglia and astrocytes accumulate around plaques and cause neuroinflammation. Here brain chemokines play a major role...

  • Alzheimer's Disease: Blocking Receptor Halts Loss of Neurons. Kingman, Sharon // BioWorld International;3/31/2010, Vol. 15 Issue 13, p1 

    The article discusses research on the possible role of a chemokine receptor present on the surface of microglial cells in the brain as treatment for Alzheimer's disease (AD). It references a study by Martin Furhmann et al, published in the March 22, 2010 issue of the journal "Nature...

  • Aβ peptide deposition in the brains of transgenic mice: evidence for a key event in Alzheimer's disease pathogenesis.  // Molecular Psychiatry;1998, Vol. 3 Issue 4, p284 

    Transgenic technology has led to the generation of several animal models for Alzheimer's disease. These transgenic mice surprisingly reproduce many aspects of the pathological alterations observed in Alzheimer's disease patients.

  • Origin and turnover of microglial cells in fibrillar plaques of APPsw transgenic mice. Wegiel, Jerzy; Imaki, Humi; Wang, Kuo-Chiang; Wegiel, Jarek; Wronska, Anetta; Osuchowski, Marcin; Rubenstein, Richard // Acta Neuropathologica;Apr2003, Vol. 105 Issue 4, p393 

    Activated microglial cells are an integral component of fibrillar plaques in brains of subjects with Alzheimer's disease (AD) and in brains of transgenic mice overexpressing amyloidogenic fragments of human amyloid precursor protein (APP). The aim of this ultrastructural study of fibrillar...

  • Amyloid Deposition and Inflammation in APPswe/PS1dE9 Mouse Model of Alzheimer's Disease. Lingfei Ruan; Zhoujun Kang; Gang Pei; Yingying Le // Current Alzheimer Research;Dec2009, Vol. 6 Issue 6, p531 

    Alzheimer's disease (AD) is characterized by amyloid plaques and neurofibrillary tangles associated with chronic inflammation. APPswe/PS1dE9 is an AD mouse model bearing mutant transgenes of amyloid precursor protein and presenilin-1. Amyloid deposition is present in this mouse model at early...

  • Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. Jing-Ji Jin; Hong-Duck Kim; Maxwell, J. Adam; Ling Li; Fukuchi, Kenichiro // Journal of Neuroinflammation;2008, Vol. 5, Special section p1 

    Background: Aβ deposits in the brains of patients with Alzheimer's disease (AD) are closely associated with innate immune responses such as activated microglia and increased cytokines. Accumulating evidence supports the hypothesis that innate immune/inflammatory responses play a pivotal role...

  • Hematopoietic CC-Chemokine Receptor 2 (CCR2) Competent Cells Are Protective for the Cognitive Impairments and Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. Naert, Gaëlle; Rivest, Serge // Molecular Medicine;Feb2012, Vol. 18 Issue 2, p297 

    Monocytes emigrate from bone marrow, can infiltrate into brain, differentiate into microglia and clear amyloid β (Aβ) from the brain of mouse models of Alzheimer's disease (AD). Here we show that these mechanisms specifically require CC-chemokine receptor 2 (CCR2) expression in bone marrow...

  • Possible Mechanism for Link Between Diabetes, Alzheimer' Disease Discovered.  // Ascribe Newswire: Medicine;2/17/2004, p17 

    For some time, researchers have known that people with diabetes have a greater risk of developing Alzheimer's disease and other forms of dementia than those without diabetes, but the exact cause of this link has not been known. Now, a new study by researchers in Cologne, Germany, and at Joslin...

  • Dimebon alters hippocampal amyloid pathology in 3xTg-AD mice. Perez, Sylvia E.; Nadeem, Muhammad; Sadleir, Katherine R.; Matras, Joanna; Kelley, Christy M.; Counts, Scott E.; Vassar, Robert; Mufson, Elliott J. // International Journal of Physiology, Pathophysiology & Pharmacol;2012, Vol. 4 Issue 3, p115 

    A double blind, placebo-controlled phase II study revealed that the antihistamine, Dimebon(r) (dimebolin, latrepirdine) improved cognition in Alzheimer disease (AD) patients compared to placebo controls. However, the Phase III CONNECTION trial failed to demonstrate significant differences...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics